274 related articles for article (PubMed ID: 33760350)
21. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
22. Metabolites of ginsenosides as novel BCRP inhibitors.
Jin J; Shahi S; Kang HK; van Veen HW; Fan TP
Biochem Biophys Res Commun; 2006 Jul; 345(4):1308-14. PubMed ID: 16729968
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
24. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
25. Deglycosylation of epithelial cell adhesion molecule affects epithelial to mesenchymal transition in breast cancer cells.
Liu X; Yang L; Zhang D; Liu T; Yan Q; Yang X
J Cell Physiol; 2019 Apr; 234(4):4504-4514. PubMed ID: 30246502
[TBL] [Abstract][Full Text] [Related]
26. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway.
Zhu M; Jiang B; Yan D; Wang X; Ge H; Sun Y
Clin Exp Pharmacol Physiol; 2020 Mar; 47(3):503-516. PubMed ID: 31788833
[TBL] [Abstract][Full Text] [Related]
28. Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport.
Ji Y; Morris ME
Pharm Res; 2004 Dec; 21(12):2261-9. PubMed ID: 15648258
[TBL] [Abstract][Full Text] [Related]
29. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
30. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.
Chen YJ; Kuo CD; Chen SH; Chen WJ; Huang WC; Chao KS; Liao HF
PLoS One; 2012; 7(5):e37006. PubMed ID: 22615870
[TBL] [Abstract][Full Text] [Related]
32. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
[TBL] [Abstract][Full Text] [Related]
33. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
34. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Ee PL; He X; Ross DD; Beck WT
Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells.
Gao J; Yan Q; Wang J; Liu S; Yang X
J Cell Physiol; 2015 Apr; 230(4):775-82. PubMed ID: 25205054
[TBL] [Abstract][Full Text] [Related]
36. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Wu DL; Huang F; Lu HZ
Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006
[TBL] [Abstract][Full Text] [Related]
37. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
[TBL] [Abstract][Full Text] [Related]
38. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
[TBL] [Abstract][Full Text] [Related]
39. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]